Search
Pimecrolimus
go.drugbank.com/drugs/DB00337ApprovedInvestigationalPimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of ato...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMegestrol acetate
go.drugbank.com/drugs/DB00351ApprovedInvestigationalVet approved17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been u...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesChlorzoxazone
go.drugbank.com/drugs/DB00356ApprovedA centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Ph...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesSapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationalSapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa ...
Categories: P-glycoprotein inhibitorsMirtazapine
go.drugbank.com/drugs/DB00370ApprovedInvestigationalMirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and recei...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTreprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigationalTreprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation. It reduces symptoms in patients with pulmonary arteri...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesTacrine
go.drugbank.com/drugs/DB00382ApprovedWithdrawnA centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has b...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCarisoprodol
go.drugbank.com/drugs/DB00395ApprovedOriginally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications . This drug is available by itse...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigationalSorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approve...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesEszopiclone
go.drugbank.com/drugs/DB00402ApprovedInvestigationalEszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as cyclopyrrolones. Cyclopyrro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates